Novartis (NVS) Stock Forecast & Price Target

$104.99 +2.06 (+2.00%)

Closing price 01/30/2025 03:59 PM Eastern

Extended Trading

$105.29 +0.30 (+0.28%)

As of 01/30/2025 07:56 PM Eastern

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 8 Analyst Ratings

Sell
2

Hold
6

Buy
0

Based on 8 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 8 analysts, 2 have given a sell rating, and 6 have given a hold rating for NVS.

Consensus Price Target

$123.38
17.51% Upside

According to the 8 analysts' twelve-month price targets for Novartis, the average price target is $123.38. The highest price target for NVS is $130.00, while the lowest price target for NVS is $120.00. The average price target represents a forecasted upside of 17.51% from the current price of $104.99.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

NVS Analyst Ratings Over Time

Type	Current Forecast 2/1/24 to 1/31/25	1 Month Ago 1/2/24 to 1/1/25	3 Months Ago 11/3/23 to 11/2/24	1 Year Ago 2/1/23 to 2/1/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	6 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	2 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$123.38	$121.50	$121.50	$99.50
Forecasted Upside	17.51% Upside	24.86% Upside	11.11% Upside	-5.53% Downside
Consensus Rating	Reduce	Reduce	Reduce	Hold

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	1.75	2.82	2.53
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	17.51% Upside	14,394.90% Upside	11.37% Upside
News Sentiment Rating	Positive News See Recent NVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/4/2024	HSBC 3 of 5 stars		Downgrade	Hold ➝ Reduce
11/19/2024	Erste Group Bank 3 of 5 stars		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets 4 of 5 stars		Boost Target	Market Perform ➝ Market Perform	$118.00 ➝ $120.00	+8.53%
9/11/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$135.00 ➝ $130.00	+11.08%
9/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$119.00 ➝ $121.00	+1.37%
9/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$114.00	+5.09%
4/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$75.00 ➝ $85.00	-13.28%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 02:41 AM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, January 29, 2025. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Recent stock performance shows resilience, with shares trading at $103.37, indicating a stable investment opportunity amidst market fluctuations.
Analysts have set a consensus price target of $123.38, suggesting potential upside for investors based on current valuations.
Institutional interest is strong, with 13.12% of the stock owned by institutional investors and hedge funds, indicating confidence in the company's future performance.
Novartis AG has a solid financial foundation, with a debt-to-equity ratio of 0.55, which suggests a manageable level of debt relative to equity, reducing financial risk.
Recent analyst upgrades, such as BMO Capital Markets raising their price objective from $118.00 to $120.00, reflect positive sentiment and potential for growth.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Some analysts have issued sell ratings, with two research analysts rating the stock as a sell, indicating concerns about its future performance.
HSBC recently downgraded Novartis from a "hold" to a "reduce" rating, suggesting that the stock may not perform as well as expected in the near term.
The stock has experienced a 1-year high of $120.92, which may indicate that it is nearing its peak, potentially limiting future gains.
Market volatility could impact Novartis AG's stock price, as seen in recent trading volumes that fluctuate significantly, which may deter risk-averse investors.
Despite a strong market cap of $211.30 billion, the P/E ratio of 12.01 may suggest that the stock is fairly valued, leaving less room for significant appreciation.

NVS Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $123.38, with a high forecast of $130.00 and a low forecast of $120.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" NVS shares.
: According to analysts, Novartis's stock has a predicted upside of 17.51% based on their 12-month stock forecasts.
: Over the previous 90 days, Novartis's stock had 1 downgrade by analysts.
: Novartis has been rated by research analysts at Erste Group Bank, and HSBC in the past 90 days.
: Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:NVS) was last updated on 1/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target